Logo

SER

Serina Therapeutics, Inc.

SER

Serina Therapeutics, Inc. • NYSE
$4.26 ▲ 8.95% (+0.35)
Market Cap $45.43 M
52w High $7.92
52w Low $3.68
Dividend Yield 0%
P/E -2.28
Volume 17.66K
Outstanding Shares 10.66M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $6.375M ▲ $-4.585M ▲ 0% ▲ $-0.444 ▲ $-4.572M ▲
Q2-2025 $130K ▲ $5.679M ▼ $-6.448M ▼ -4.96K% ▼ $-0.64 ▼ $-6.437M ▼
Q1-2025 $0 ▲ $5.841M ▲ $-4.813M ▼ 0% ▼ $-0.493 ▼ $-4.805M ▼
Q4-2024 $-14K ▼ $5.535M ▲ $-2.74M ▼ 19.571K% ▲ $-0.31 ▼ $-2.679M ▼
Q3-2024 $14K $5.326M $1.41M 10.071K% $0.16 $1.455M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.62M ▲ $12.413M ▲ $10.819M ▲ $1.76M ▼
Q2-2025 $6.041M ▲ $8.941M ▲ $7.295M ▲ $1.802M ▲
Q1-2025 $4.267M ▲ $6.731M ▲ $5.172M ▼ $1.701M ▲
Q4-2024 $3.672M ▲ $6.724M ▼ $6.216M ▼ $641K ▲
Q3-2024 $3.185M $7.435M $21.263M $-13.774M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.585M ▲ $-3.85M ▼ $-13K ▲ $6.444M ▲ $2.579M ▲ $-3.863M ▼
Q2-2025 $-6.462M ▼ $-3.75M ▲ $-46K ▼ $5.57M ▲ $1.774M ▲ $-3.75M ▲
Q1-2025 $-4.822M ▼ $-4.322M ▲ $0 ▲ $4.917M ▼ $595K ▲ $-4.322M ▲
Q4-2024 $-2.752M ▼ $-4.589M ▼ $-5K ▼ $5.031M ▲ $437K ▲ $-4.594M ▼
Q3-2024 $1.383M $-2.962M $-3K $86K $-2.879M $-2.965M

Five-Year Company Overview

Income Statement

Income Statement Serina’s income statement looks like a classic early‑stage biotech: there is essentially no product revenue yet, and the small amounts of spending show up as operating losses. The company has reported slight ups and downs in profit and loss, but these swings are more about accounting items and financing events than about a real underlying business. Earnings per share have bounced around sharply, which is typical when a tiny company combines losses with share structure changes. Overall, the story here is simple: Serina is still in the research and development phase, not in the commercial sales phase, and its income statement reflects that.

Balance Sheet

Balance Sheet The balance sheet is very small and quite thin. Serina reports only modest total assets and effectively no meaningful cash cushion in the snapshot provided. Debt is minimal, which reduces financial strain from interest, but equity has hovered around break‑even and was negative in some earlier years. That pattern suggests the company has historically relied on external funding to keep going and has limited buffer to absorb setbacks. The recent reverse stock split also signals a focus on maintaining listing standards rather than reflecting underlying business strength. In short, the balance sheet shows a fragile but mostly unleveraged financial base, highly dependent on future capital raises and partnerships.

Cash Flow

Cash Flow Cash flow trends reinforce the picture of an R&D‑stage biotech. Operating cash flow is consistently negative, reflecting ongoing development and overhead costs without offsetting revenue. Free cash flow tracks operating cash flow closely because there is essentially no meaningful capital spending on plants or equipment. That means virtually all cash burn is tied to running and advancing the pipeline. The absolute level of cash burn in the historical data appears modest, but this can change quickly as clinical trials scale up. With little internal cash generation, Serina’s ability to fund its plans will likely hinge on raising money from investors and securing milestone or licensing payments from partners.

Competitive Edge

Competitive Edge Competitively, Serina is trying to differentiate itself with its POZ Platform, a polymer‑based drug delivery technology aimed at making drugs longer‑acting, more stable, and potentially safer. The platform is designed to be versatile, usable across small molecules, proteins, and even RNA‑related delivery systems. A notable strength is third‑party validation: a licensing deal with a major pharma player (Pfizer) supports the idea that the underlying chemistry has real value. Partnerships like the one with Enable Injections further enhance the potential appeal of Serina’s lead product in Parkinson’s disease by focusing on patient convenience. On the other hand, Serina is a very small company operating in a crowded field where larger competitors also work on long‑acting formulations and neurology treatments. Its competitive position is therefore promising but still largely theoretical, and it remains highly dependent on successful clinical data and the ability to stand out in a busy space.

Innovation and R&D

Innovation and R&D Innovation is where Serina clearly leans in. The POZ Platform aims to solve known problems with older polymer technologies by improving control over drug release and reducing unwanted immune reactions. The company’s strategy is to take drugs that already work and re‑engineer how they are delivered, aiming for fewer doses, smoother symptom control, and better patient experiences. SER‑252 for advanced Parkinson’s disease is the lead test of this idea, with the goal of providing continuous relief through simple, infrequent injections instead of pumps. SER‑270 for tardive dyskinesia is a follow‑on project in a similar spirit. The Pfizer licensing deal highlights that the platform may have value beyond Serina’s own pipeline. However, the recent FDA clinical hold on SER‑252 introduces a significant uncertainty: even if the issue is tied to a formulation component and not the active drug itself, it still pauses progress and must be resolved convincingly. Overall, the company’s value is heavily tied to its R&D execution and regulatory interactions; innovation is the clear strength, but it comes with high technical and regulatory risk.

Summary

Putting it all together, Serina Therapeutics is an ultra‑early, platform‑driven biotech with no commercial revenue yet, a thin balance sheet, and ongoing cash burn. The financials show a company that lives on external capital and partnerships rather than internal cash generation. The real attraction lies in its POZ drug‑delivery technology, the focused neurology pipeline, and important external validation from a global pharma partner. At the same time, Serina operates from a position of financial fragility, faces intense competition from larger players, and is dealing with a clinical hold on its lead program—underscoring both regulatory and execution risk. Future outcomes will hinge on three main threads: resolving regulatory questions around SER‑252, generating compelling clinical data for its pipeline, and securing enough funding and partnerships to carry the platform through to proof of concept and, eventually, potential commercialization.

NEWS

November 13, 2025 · 6:10 AM UTC

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Read more

November 3, 2025 · 6:05 AM UTC

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Read more

October 29, 2025 · 7:00 AM UTC

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Read more

October 8, 2025 · 11:00 AM UTC

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Read more

October 6, 2025 · 4:15 PM UTC

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Read more